Can tumor profiling help kids beat cancer? new study aims to find out
NCT ID NCT02520713
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether testing the genes of a child's solid tumor can help doctors choose a more effective treatment. About 825 children and young adults with hard-to-treat solid tumors will have their tumors genetically profiled. The goal is to see if those who receive a treatment matched to their tumor's genetic changes live longer than those who do not.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Genetic testing and tumor profiling
- What this could lead to
- If successful, this could help doctors better match cancer treatments to a child's specific tumor genetics, potentially improving survival.
- What could go wrong
- This is an observational study, not a treatment trial. It may not prove that matching therapy improves outcomes, and many patients may not get a matching recommendation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 825 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2015
- Expected to finish
-
Oct 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
High-risk, relapsed and refractory solid tumors
- Ages
-
Up to 30 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age -- Age ≤ 30 years at time of initial qualifying solid tumor diagnosis * Diagnosis -- Histologic diagnosis of solid malignancy (excluding brain tumors and lymphoma) that meets at least one of the following criteria: * Refractory, defined as tumor progression after initiation of standard first line therapy without having achieved a prior partial or complete remission OR Biopsy proven residual disease at the completion of planned standard initial front-line therapy. * Recurrent, defined as tumor progression after achieving a prior partial or complete remission * Newly diagnosed high risk disease, defined as having an expected event free survival of \< 50% at 2 years. * Lacks definitive diagnosis or classical genomic findings after histologic review and standard molecular testing (rare tumor group). * Examples include (eligibility not limited to these examples): * Histology typically associated with a fusion in which fusion is not detected. * Ewing-like sarcoma * Undifferentiated sarcoma * Inflammatory myofibroblastic tumor without ALK fusion * Infantile fibrosarcoma without NTRK fusion * Specimen Samples * Sufficient tumor specimen available to meet the minimum requirements for profiling from diagnosis or progression / recurrence \--- OR * Surgery / biopsy planned as part of clinical care that is anticipated to yield sufficient material to meet the minimum requirements for profiling; OR * Patient has already had molecular profiling and patient has not yet started matched targeted therapy based on the report . Exclusion Criteria: * No Therapy Planned \-- Patients who have declined further anticancer therapy will be excluded. * Performance Status \-- Patients with Lansky (age \< 16 years) or Karnofsky (age ≥16 years) score \< 50 will be excluded. * Life Expectancy -- Patients with anticipated life expectancy \< 3 months will be excluded.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pediatric solid tumor are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Boston Children's Hospital
Boston, Massachusetts, 02215, United States
-
Children's Hospital Colorado
Aurora, Colorado, 80045, United States
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Children's National Medical Center
Washington D.C., District of Columbia, 20010, United States
-
Columbia University Medical Center
New York, New York, 10032, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Nationwide Children's Hospital
Columbus, Ohio, 43205, United States
-
Seattle Children's Hospital
Seattle, Washington, 98105, United States
-
University of California San Francisco
San Francisco, California, 94158, United States
-
University of Chicago Comer Children's Hospital
Chicago, Illinois, 60637, United States
-
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas, 75390, United States
-
University of Utah Childrens Medical Center
Salt Lake City, Utah, 84113, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- First human test of BI 4060107 aims to find safe dose for Hard-to-Treat tumors
- Can a new drug shield kidneys from chemotherapy damage?
- Mining Responders' tumors for clues to a universal cancer therapy
- Proton boost radiotherapy aims to hit large tumors harder while sparing healthy tissue
- New antibody aims to preserve immune checkpoint while fighting cancer
- Engineered immune cells target two markers on Hard-to-Treat tumors